Response of osteosarcoma to chemotherapy: Evaluation with F-18 FDG-PET scans

Clinical Positron Imaging (Netherlands)

Volumn 3, Issue 2, 2000, Pages 79-83

  Nair, Narendra ^a   Ali, Amjad ^a   Green, Alexander A ^a   Lamonica, Greg ^a   Alibazoglu, Haluk ^a   Alibazoglu, Buket ^a   Hollinger, Edward F ^a   Ahmed, Kamran ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

FDG PET; Osteosarcoma; Tumor viability

Indexed keywords

EID: 0002687052     PISSN: 10950397     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1095-0397(00)00037-6     Document Type: Article

References (24)

1. A.G. Huvos G. Rosen R.C. Marcove Primary osteogenic sarcoma pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement Arch. Pathol. Lab. Med. 101 1977 14 18
2. A.K. Raymond S.P. Chawla C.H. Carraso Osteosarcoma chemotherapy effect a prognostic factor Semin. Diagn. Pathol. 4 1987 212 236
3. G. Rosen B. Caparros A.G. Huvos Preoperative chemotherapy for osteogenic sarcoma selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy Cancer 49 1982 1221 1230
4. P. Picci G. Bacci M. Campanacci Histologic evaluation of necrosis in oesteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor Cancer 56 1985 1515 1521
5. P. Som H.L. Atkins D. Bandhopadhya A fluorinated glucose analogue, 2-fluoro-2-deoxy-D-glucose (F-18):non-toxic tracer for rapid tumor detection J. Nucl. Med. 21 1980 670 675
6. K.B. Nolop C.G. Rhodes L.H. Brudin Glucose utilization in vivo by human pulmonary neoplasms Cancer 60 1987 2682 2689
7. H.N. Wagner Jr Clinical PET its time has come J. Nucl. Med. 32 1991 561 564
8. L.P. Adler J.P. Crowe N.K. Al-Kaisi J.L. Sunshine Evaluation of breast masses and axillary lymph nodes with [18F] 2-deoxy-2-fluoro-D-glucose PET Radiology 187 1993 743 750
9. N. Avril J. Dose F. Janicke Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose J. Clin. Oncol. 14 1996 1848 1857
10. L. Chaiken S. Rege C. Hoh Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 27 1993 455 464
11. T. Bury A. Dowlati P. Paulus T. Hustinx M. Radermecker P. Rigo Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography Eur. J. Nucl. Med. 23 1996 204 206
12. T. Inoue E.E. Kim R. Komaki Detecting recurrent or residual lung cancer with FDG-PET J. Nucl. Med. 36 1995 788 793
13. G. Beets F. Penninckx C. Schiepers Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer Br. J. Surg. 81 1994 1666 1670
14. N. Gupta H. Bradfield Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms Semin. Nucl. Med. 26 1996 65 73
15. K.A. Kern A. Brunetti J.A. Norton Metabolic imaging of human extremity musculoskeletal tumors by PET J. Nucl. Med. 29 1988 181 186
16. L.P. Adler H.F. Blair J.T. Makley Noninvasive grading of musculoskeletal tumors using PET J. Nucl. Med. 32 1991 1508 1512
17. J.R. Garcia E.E. Kim C.L. Franklin Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas J. Nucl. Med. 37 1996 1476 1479
18. Abella, E.; DiCarli, M.; Ravindranath, Y.; et al. Positron emission tomography [PET] scanning with 18-fluorodeoxyglucose [FDG] correlates with histological response in children with osteosarcoma [OS] and Ewing's sarcoma [ES]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 15:1457; 1996.
19. W. Kumpan G. Lechtner G.R. Witich The angiographic response of osteosarcoma following pre-operative chemotherapy Skeletal. Radiol. 15 1986 96 102
20. C.H. Carrasco C. Charnsangavej A.K. Raymond Osteosarcoma angiographic assessment of response to preoperative chemotherapy Radiology 170 1989 839 842
21. V. Bonnerot A. Charpentier F. Frouin C. Kalifa D. Vanel R. Di Paola Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy Invest. Radiol. 27 1992 847 855
22. R. Erlemann M.F. Reiser P.E. Peters Musculoskeletal neoplasms static and dynamic Gd-DTPA-enhanced MR imaging Radiology 171 1989 767 773
23. T. De Baere D. Vanel L.G. Shapeero Osteosarcoma after chemotherapy evaluation with contrast material-enhanced MR imaging Radiology 185 1992 587 592
24. M. Meyer R. Gast S. Raja K. Hubner Increased F-18 FDG accumulation in an acute fracture Clin. Nucl. Med. 19 1994 13 14